Revolution Medicines · 2 weeks ago
Scientist II, Cancer Pharmacology, Translational Research
San Francisco Bay Area
Full-time
Hybrid
Entry, Mid Level
$128K/yr - $160K/yr
2+ years expRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. As a Scientist II in the Translational Research team, you will collaborate with team members to develop and refine pharmacokinetic models and conduct experiments to support cancer drug discovery.
Health CareLife ScienceMedical
Responsibilities
As a member of a cross-functional quantitative modeling group, collaborate with team members to develop, validate and refine physiologically-based PK (PBPK), quantitative systems pharmacology (QSP), and semi-mechanistic PK/PD models to support discovery and development-phase projects
Propose mechanistic in vitro and in vivo experiments to test model assumptions and structure
Seek and apply innovative modeling approaches to understand tumor resistance to RAS(ON) inhibitors and build in silico models
Design, conduct, and manage in vivo and ex vivo experiments in-house or at contract research organizations (CROs), and other collaborating institutions, to support above modeling activities
Present results at internal meetings and scientific conferences
Develop high-quality protocols and outputs and maintain detailed documentation of procedures and data to comply with internal standard operating procedures and other quality criteria, where necessary
Qualification
Required
Ph.D. with quantitative science background (pharmaceutical sciences, mathematics, systems pharmacology, computational biology, etc.); or Ph.D. in pharmacology or cancer biology or a related discipline with modeling experience
2+ years of relevant postdoc or industry experience in cancer drug discovery and development
A strong theoretical understanding of the core concepts, assumptions, and limitations associated with PK/PD modeling
Experience with development, calibration, and validation of ordinary differential equation (ODE) and non-linear mixed effect (NLME) models
Rigorous, quantitative and detail-oriented with proven excellence in experimental design, data analysis, data management, and presentation
Excellent written and verbal communication skills. Able to effectively communicate modeling assumptions, limitations, and simulation results to non-specialist and specialist audiences
Demonstrated ability to multi-task, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important
Thrives in a collaborative team setting and is driven by a desire to be innovative in a dynamic and fast-paced environment
Preferred
Solid PK/PD knowledge and prior experience with PK/PD data collection and analysis
An understanding of preclinical to clinical translational concepts desired
Hands on experience with modeling software (Simbiology, Phoenix WinNonlin, NONMEM, etc.) and PBPK model development
Demonstrated experience in in vivo experiments with oncology disease models
Strong track record of research productivity as evidenced by high-quality, impactful publications
Benefits
Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities
Company
Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
501-1000 employees
H1B Sponsorship
Revolution Medicines has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (18)
2023 (15)
2022 (8)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$2.25BKey Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M
Leadership Team
Luan Wilfong
Chief Human Resources Officer
Steve Kelsey
President
Recent News
2026-01-11
The Motley Fool
2026-01-11
Company data provided by crunchbase